Method to determine the state of the humoral immune system in a patient 

AGRA – Acellular growth retardation ability

Granted patent in Europe (EP3431988B1)​

Consortium:

CBmed logo   

Background

Bacterial infections in patients with cirrhosis are a frequent and life-threatening complication, which are difficult to predict

Clinical need

Currently, it is not possible to reliably predict susceptibility and the risk of infection in cirrhosis. Therefore, tools to predict severe infections are an urgent clinical need and will help to reach the goal of precision medicine.

Kaplan-Meier-curve for the probability to live without infection. Patients with high AGRA have a significantly higher risk to develop infections compared to patients with low AGRA.

Kaplan-Meier-curve for the probability to live without infection. Patients with high AGRA have a significantly higher risk to develop infections compared to patients with low AGRA.

Our solution

We invented AGRA, a reliable, easy-to-assess, functional biomarker with the possibility for fully automated handling that utilizes the growth tendencies of a specific strain of bacteria in human serum to predict the outcome of a patient.

Effects & benefits

AGRA predicts the occurrence of severe infections in patients with liver cirrhosis, accurately identifies patients at risk of infections, tracks treatment success and helps to create personalized risk-assessment and treatment of patients with liver cirrhosis.

We believe in further applications of AGRA beyond liver disease and are actively looking for partners to join our research.

AGRA in patients who will develop a severe infection in the next 36 months, or not.

Are you interested in a collaboration on this patent? Get in contact with our Business Development Team:

Julia Schmidt
Business Development Manager

Further information on the patent

Read our blog post to AGRA

The COMET Center CBmed is funded within COMET – Competence Centers for Excellent Technologies by the Federal Ministry of Climate Action, Environment, Energy, Mobility, Innovation and Technology (BMK), the Federal Ministry for Digital and Economic Affairs (BMDW), Land Steiermark (Styrian Business Promotion Agency – SFG) and Land Wien (Vienna Business Agency – WAW). The COMET program is executed by the Austrian Research Promotion Agency (FFG).

CBmed GmbH Center for Biomarker Research in Medicine
Stiftingtalstrasse 5   8010 Graz   Austria   office@cbmed.at   +43 316 385 28801

PRESS CORNER     CONTACT     IMPRINT     PRIVACY

Font Resize
Contrast